MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Caladrius Biosciences ROE Ratio 2011-2026 | CLBS
Annual ROE Ratio Caladrius Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -67.58 | -43.28 | -81.45 | -29.77 | -25.28 | -94.2 | -43.16 | 45.78 | -803.06 | -347.39 | -94.49 | -62.85 | -163.83 | -58.82 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.78 | -803.06 | -133.53 |
Quarterly ROE Ratio Caladrius Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -79.99 | -70.27 | -61.4 | -40.66 | -50.64 | -45.88 | -39.58 | -27.15 | -79.24 | -121.34 | -122.43 | -64.94 | -71.98 | -26.93 | -24.28 | -19.77 | -36.16 | -45.51 | -19.79 | -8.37 | -31.9 | -39.03 | -84.03 | -69.2 | -78.61 | -64.49 | -50.6 | -33.43 | -40.45 | -38.07 | 48.9 | 49.74 | -99.47 | -241.67 | -479.27 | -557.34 | -557.48 | -408.32 | -246.94 | -0.34 | -0.22 | -0.2 | -0.15 | -0.09 | -0.09 | -0.08 | -0.07 | -0.06 | -25.39 | -50.73 | -112.52 | -115.33 | -127.18 | -113.67 | -68.96 | -45.34 | -11.84 | -17.1 | -16.4 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.74 | -557.48 | -81.08 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.58 | 0.42 % | $ 1.07 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-28.74 | $ 3.22 | 2.88 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.79 | - | $ 4.31 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-138.5 | $ 4.2 | -0.47 % | $ 105 M | Schweiz |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 231.11 | 0.03 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.45 | -4.43 % | $ 8.3 B |  Australia |
 |
Atea Pharmaceuticals
AVIR
|
-57.49 | $ 6.02 | -0.5 % | $ 491 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 6.59 | -0.6 % | $ 180 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
BioCardia
BCDA
|
721.83 | $ 1.29 | 1.57 % | $ 27.3 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.36 | - | $ 210 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
559.76 | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
BioNTech SE
BNTX
|
1.11 | $ 91.71 | 1.29 % | $ 27.2 B | Germany |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.64 | - | $ 16.6 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.17 | 1.49 % | $ 1.33 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.51 | -0.33 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
-216.19 | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 3.58 | -0.28 % | $ 7.79 B | Israel |